Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with idiopathic Parkinson's disease~* Disease duration of at least 5 years or more~* Adequate duration of levodopa therapy~* Modified Hoehn and Yahr Staging of at least 2.5 in the OFF state~* Candidate for surgical intervention because of disabling motor complications.~* UPDRS Part III (total motor) score ≥ 25 and a maximum of 60 in the OFF state.~* Unequivocal responsiveness to dopaminergic therapy.~* Stable Parkinson's symptoms and medication regimen for at least 4 weeks prior to screening examination.~* Ability to comprehend and sign the informed consent.~* Normal Laboratory values prior to surgery.~* Neutralizing AAV2 antibody titer ≤ 1:1200~* Ability to travel to study visits alone or able to designate a caregiver.~* Subject agrees to defer any neurological surgery, including deep brain stimulation, until after completing the 12 month study visit (unless recommended by study neurologist).~* Subject agrees to not participate in any other therapeutic intervention study for 12 months after surgery.~* Subject agrees to not have any vaccinations within 30 days of surgery.~Exclusion Criteria:~* Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals or toxins.~* Presence of dementia as defined by a Mattis Dementia Rating Scale-Second Edition (MDRS-2) of less than 130 at screening.~* Presence or history of psychosis, with the exception of mild, benign hallucinations believed in the judgment of the investigators to be related to Parkinson's medications.~* Presence of severe depression as measured by Beck Depression Inventory II (BDI-II) \> 28 or a history of a major affective disorder within 5 years of screening examination.~* Current suicidal ideation or suicide attempt within 5 years of screening examination.~* History of substance abuse within 2 years of screening examination.~* Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery.~* Contraindication to MRI and/or gadoteridol.~* Coagulopathy or inability to temporarily stop any anticoagulation or antiplatelet prior to surgery.~* Prior brain surgery including deep brain stimulation, infusion therapies or any other brain surgery.~* Prior gene transfer.~* History of stroke, poorly controlled or significant cardiovascular disease, diabetes or any other acute or chronic medical condition.~* History of malignancy other than treated carcinoma in situ within three years of screening evaluation.~* Clinically apparent or laboratory-detected infection.~* Prior or current treatment with any investigational agent within 2 months of screening evaluation.~* Chronic immunosuppressive therapy, including chronic steroids, immunotherapy, cytotoxic therapy and chemotherapy.~* Pregnant and lactating women.~* Subject with reproductive capacity who is unwilling to use barrier contraception.~* Any medical condition that is likely to lead to disability during the course of the study and interfere with confound study assessments~* Any factors, medical, or social, which would likely cause the subject to be unable to follow the study protocol, including geographical inaccessibility.~* Ongoing treatments such as, neuroleptic medications, apomorphine, or levodopa infusion therapy (Duodopa®).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VY-AADC01 Dose 1 (Type: EXPERIMENTAL): 7.5 x 10\^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
- VY-AADC01 Dose 2 (Type: EXPERIMENTAL): 1.5 x 10\^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
- VY-AADC01 Dose 3 (Type: EXPERIMENTAL): 4.7x 10\^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete